Companies To Watch
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
-
![CtW - Qlaris_450x300]( "Companies To Watch: Qlaris Bio")
Companies To Watch: Qlaris BioQlaris Bio is striking at an unaddressed target in the intraocular pressure of glaucoma.
-
![Ctw_Graphite Bio_450x300]( "Companies To Watch: Graphite Bio")
Companies To Watch: Graphite BioGraphite Bio focuses on precise repair of genes that cause sickness, starting with Sickle Cell Disease.
-
![CtW Atea_450x300]( "Companies To Watch: Atea Pharmaceuticals")
Companies To Watch: Atea PharmaceuticalsAtea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.
-
![CtW_Judy Chou 450x300]( "Companies To Watch: AltruBio")
Companies To Watch: AltruBioAltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.
-
![CtW_AMO_Ibraheem Mahmood_450x300]( "Companies To Watch: AMO Pharma")
Companies To Watch: AMO PharmaAMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.
-
![CtW_Paul Brennan_450x300.jpg]( "Companies To Watch: NervGen Pharma")
Companies To Watch: NervGen PharmaNervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.
-
![CTW_IM_450x300]( "Companies To Watch: IM Therapeutics")
Companies To Watch: IM TherapeuticsOur company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.
-
![CtW_450x300.jpg]( "Companies To Watch: Lyra Therapeutics")
Companies To Watch: Lyra TherapeuticsOur company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.
-
![CtW - Carisma TX_450x300]( "Companies To Watch: Carisma Therapeutics")
Companies To Watch: Carisma TherapeuticsCarisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.
-
![CtW_PhaseBio_450x300.jpg]( "Companies To Watch: PhaseBio")
Companies To Watch: PhaseBioPhaseBio is a small, public company aiming to enter a large-market therapeutic area: cardiovascular.
-
![CtW - Akero_450x300.jpg]( "Companies To Watch: Akero Therapeutics")
Companies To Watch: Akero TherapeuticsCompanies To Watch: Akero Therapeutics - Test-proofing a new metabolism drug to beat the liver disease, NASH
-
![CtW_Joe Lobacki_450x300.jpg]( "Companies To Watch: Artax Biopharma")
Companies To Watch: Artax BiopharmaArtax Biopharma is challenging the immunosuppressive paradigm with a novel drug for autoimmune diseases.
-
![CtW_Ridgeback_Wendy_450x300]( "Companies To Watch: Ridgeback Biotherapeutics")
Companies To Watch: Ridgeback BiotherapeuticsRidgeback Biotherapeutics is pitting new and potent antivirals versus COVID, Ebola, and other coronaviruses.
-
![CtW_Osivax_450x300.jpg]( "Companies To Watch: Osivax")
Companies To Watch: OsivaxOsivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.
IN THIS MONTH'S ISSUE
BEYOND THE PRINTED PAGE
-
Starting A Company … In Another Country1/17/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, discusses challenges associated with building a biopharma startup in another country.
-
A Lesson In Leadership From Lara Sullivan12/22/2021
Lara Sullivan, M.D., CEO of Pyxis Oncology, shares a story showing the impact had by employees in creating the right corporate culture.
-
The Path That Brought Lara Sullivan To Biopharma12/20/2021
Lara Sullivan, M.D., to be featured in an upcoming issue of Life Science Leader, discusses the entrepreneurial path the brought her to the CEO role at Pyxis Oncology.
LIFE SCIENCE LEADER BLOGS
-
![2021_Rob Wright headshot]( "How Will It End?")
The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.
-
![Back to the office]( "When Will Biopharma Be Back In The Office?")
Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.
